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Chronic beryllium disease (CBD) is typically considered only when occupational exposure to
beryllium is acertainty; however, CBD has also occurred inoccupationalandenvironmental set-
tingswhere exposure was uneected. When theetiologyofa caseofgranulomatous pulmonary
disease is not determined, sarcoidosis is the "diagnosis ofexclusion." This diagnosis does not
coum cate much information about the patient's prognosis, the disease's etiology, or even
what disease iologies were specific excluded. Some cass ofCBD have beencalled sarcoido-
sis, allowing exposure to continue for the patient and (at times) other individuals. The granulo-
matous changes ofsarcoidosis are thought to result from an abnormal une response. Whie
theetiologic agents that caninitiate this response are la unknown, the io pathogenesis
ofCBD has beenwelldecribed andlaboratoy methods are available in afw.centers thatcan
(ifused) identifyberylihum .hyerenity Thepotential for exposure.andisse to bewidely
separated in time andlocation rtant for health-care and l hea pro
fesionas to be awareofthese newdiagostic.methods. Ky w b , eryllium, granu-
lomatous, hypersensitive, lrmphocyte, pulmonary, sarcoidosis. Environ Health Perspect
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Beryllium-induced lung diseases can usually
be categorized as either an acute or a chronic
disease process. After briefly reviewing acute
beryllium disease (ABD), this paper reviews
chronic beryllium disease (CBD) and
explores state-of-the-art diagnostic advances.
Acute Beryllium Disease
Inhaling high concentrations of beryllium
can lead to acute chemical pneumonitis
with dyspnea, cough, and chest pain.
Physical examination of these patients
reveals tachypnea with inspiratory rales and
tachycardia. Pulmonary infiltrates are usual-
ly seen on the chest X ray, and arterial
blood gases typically reveal hypoxemia (1).
This acute process has occasionally resulted
in death; ifthe patient survives the acute ill-
ness, recovery is typically complete.
The first cases ofABD in the United
States were reported in 1943; the exposures
occurred while workers were extracting
beryllium oxide from beryllium ore. The
physicians reporting these cases were initially
unsure about the role ofberyllium, condud-
ing that the chemical pneumonia in three
workers was due to "chemical compounds
formed outside or inside the respiratory tract
during the processing ofthe ore" (2).
By the time of a follow-up report in
1945 (3), this group ofresearchers had seen
170 cases of acute beryllium poisoning. In
these cases, the symptom complexes includ-
ed dermatitis, chronic skin ulcers, and pneu-
monitis; five of these workers had died.
With advances in industrial hygiene, ABD
has been virtually eliminated in the United
States: there were 53 acute cases reported in
1947, 28 in 1948, and 1 in 1949 (4).
A committee of experts was assembled
in 1950 by theAtomic Energy Commission
to recommend safe levels ofberyllium in air
(4). Other than rare cases resulting from
accidental exposures, ABD is no longer a
problem in theUnited States.
Chronic Beryllium Disease
While ABD is mostly ofhistorical signifi-
cance in this country (5), cases of CBD
continue to occur. The inflammatory
process ofCBD is characterized by the for-
mation of noncaseating granulomas that
contain predominantly epithelioid cells
and lymphocytes. While case reports have
included other organ systems, the lungs are
the primary site of involvement. An
unknown number of CBD cases are not
properly diagnosed (6).
Most cases of CBD result from pro-
longed or multiple ambient exposures to
beryllium. When exposure is uncertain, it is
sometimes possible to demonstrate excess
beryllium inbiopsyspecimens from thelung
using laser microprobe mass spectrographic
analysis.
The symptoms that cause the patient to
seek medical evaluation can include
arthralgias, chest pain, cough, or (most
commonly) dyspnea with relatively mild
exertion. Physical examination may reveal
hepatosplenomegaly, inspiratory rales, and
lymphadenopathy. The chest Xraytypical-
ly reveals diffuse infiltrates and frequently
reveals hilar lymphadenopathy. Computed
tomography can accurately characterize the
extent ofdisease, but cannot reliablydiffer-
entiate between CBD and sarcoidosis (7).
Pulmonary functioning (especially exercise
tolerance) eventually becomes abnormal,
although air flow patterns can be restrictive,
obstructive, or even normal with a reduced
diffusingcapacity (8).
CBD is a progressive disease that often
requires treatment with corticosteroids for
life. Preventing additional exposure is an
important aspect of therapy, but does not
arrest the disease process in most patients. In
one sense, exposure continues: beryllium
deposited in the patient's lungs provides per-
sistent antigenic stimulation over time ($l.
Epidemiology ofCBD. The first cases of
CBD in the United States were reported in
1946; these exposures occurred while work-
ers were manufacturing fluorescent lamps.
The U.S. Beryllium Case Registry (currently
inactive) was established in 1952 at the
Massachusetts Institute ofTechnology and
maintained after 1978 by the National
Institute for Occupational Safety and Health
(NIOSH). This registry contains approxi-
mately 900 cases of CBD; entering a case
into the registry required documentation of
beryllium exposure, either by history or by
demonstration ofexcess beryllium in biolog-
ic specimens, plus any three of the clinico-
pathologic criteria summarized below (10):
1.Clinical symptoms of a lower respiratory
tract disorder
2.Reticulonodular infiltrates on chest radi-
ography
3.Restrictive or obstructive impairment of
pulmonary function or a depressed diffus-
ing capacity for carbon monoxide
4.Histologic demonstration of noncaseating
granulomas and/or mononuclear cell inter-
stitial infiltrates on lungbiopsyspecimens.
The number of CBD cases that could
meet the definition, but were not identified
and added to the registry is unknown.
There is evidence that sarcoidosis is diag-
nosed without adequately excluding CBD
(6). Also, researchers using modern labora-
tory methods have shown that some
patients who do not meet the registry crite-
ria do have CBD (11). After taking a thor-
ough exposure history, the clinical diagnosis
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of CBD can be adequately supported by
demonstrating both pulmonary granulomas
and immune responsiveness to beryllium.
Besides occupational cases ofberyllium,
the registry also contains 65 nonoccupa-
tional (environmental) cases reported
before 1960: 23 cases resulted from expo-
sure to dust brought home on work clothes
and 42 cases resulted from off-site air pol-
lution. With improvements in industrial
hygiene, environmental cases ofCBD were
thought to have disappeared. However,
Newman and Kreiss (12) recently reported
a case that resulted from what appeared to
be a brief, low-level exposure; this report
suggested that although environmental
cases are rarelydiagnosed, they do occur.
Immunology ofCBD. The early health
studies ofberyllium were difficult to inter-
pret because the dose that produced disease
appeared to vary considerably, disease
severity did not correlate with tissue levels,
and the latency period was often long
(13,14). These characteristics lead (as early
as 1951) to the postulation of an immune
mechanism (15); however, because berylli-
um has a very low molecular weight, this
ability to induce an immune response was
unexpected. Much ofthe research on CBD
has focused on understanding this immune
response and developing a reliable test for
beryllium hypersensitivity (16).
In 1951, cutaneous hypersensitivity to
beryllium was described and a patch test
developed; a positive test at 72 hr was con-
sidered evidence of beryllium hypersensi-
tivity and of CBD in patients with granu-
lomatous lung disease (17,18). However,
cutaneous hypersensitivity developed in 8
of 16 previously unexposed controls, and at
least one fatality was associated with the
patch test (19). The patch test was never
widely used and is rarely used today
because of safety concerns and the test's
proven ability to induce hypersensitivity.
Two in vitro tests have been developed
to test for hypersensitivity to beryllium: the
migratory inhibitory factor (MIF) test and
the lymphocyte proliferation test (LPT).
MIF is secreted by activated T lymphocytes
during antigenic stimulation to keep
macrophages from migrating. In theory,
identifying hypersensitive people by incu-
bating lymphocytes from the blood or bron-
choalveolar fluid with beryllium and testing
for MIF should be possible. In practice, this
test is technically difficult and gives results
that are both insensitive (even to well-estab-
lished CBD) and difficult to reproduce (20).
The MIF test is no longer used.
The current test for beryllium hyper-
sensitivity is the LPT (20). In the LPT,
lymphocytes are taken from the peripheral
blood or from bronchoalveolar fluid (21)
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and exposed in vitro to beryllium sulfate. If
the patient is hypersensitive, T lympho-
cytes will proliferate. Typically, a stimula-
tion index is determined by comparing
proliferation among lymphocytes incubat-
ed with andwithout beryllium sulfate.
Rossman et al. (22) looked at the sensi-
tivity and specificity ofthe LPT in a small
series of cases and controls; bronchoalveo-
lar lymphocytes were exposed in vitro to
beryllium sulfate; a positive proliferative
response was defined as a stimulation index
greater than 5 on two separate determina-
tions. The 23 beryllium workers evaluated
in the study included 14 patients who
clearly met the registry case definition for
CBD (described above). For these 14
patients, the sensitivity of the proliferation
test was 100%. The 22 controls selected
included 16 patients with sarcoidosis and 6
normal volunteers; none of the controls
had positive proliferative tests (100% speci-
ficity for these 22 controls). When the pro-
liferation tests were repeated with lympho-
cytes from peripheral blood, the sensitivity
for CBD was lower.
Kreiss et al. (23) demonstrated the util-
ity of screening the peripheral blood of
exposed workers using the LPT. The test
identified several new cases ofCBD among
nuclear workers and in the ceramics indus-
try (24,25). The "predictive value positive"
ofa confirmed test in the ceramics workers
was 100%, but two cases of CBD initially
identified by chest X ray did not have con-
sistently abnormal blood tests. In other
words, while a positive blood test can con-
firm CBD, a negative blood test (alone)
does not exclude it.
Genetics ofCBD. CBD is an immune
hypersensitivity disorder caused by an
interaction between beryllium and sensi-
tized helper (CD4+) T lymphocytes. For
this interaction to occur, the small berylli-
um molecules must first be bound to a car-
rier protein. The antigen (a beryllium/pro-
tein complex) is then processed and pre-
sented to T lymphocytes by a major histo-
compatibility complex Class II molecule.
This molecule consists ofan a-chain and a
3-chain that interact to bind the antigen.
Because the substitution of a single amino
acid can determine what antigen is bound,
Richeldi et al. (26) recently studied the
genes that encode the 1-chain in 33 cases
(exposed workers with CBD) and 44 con-
trols (exposed workers without CBD).
These researchers found that 97% (32/33)
ofthe cases exhibited the amino acid gluta-
mate (rather than lysine) at position 69 ofa
cell-surface glycoprotein involved in anti-
gen recognition. This marker (Glu69) was
present in only 30% (13/44) of the con-
trols, suggesting a significant genetic role in
the immune process leading to CBD. This
finding could have relevance forcounseling
in certainoccupational settings (26).
Differential Diagnosis of CBD
The known causes ofgranulomatous dis-
ease (with examples in parentheses) are
bacterial (brucellosis, leprosy, salmonel-
losis, and tuberculosis), fungal (blastomy-
cosis, coccidiomycosis, andhistoplasmosis),
viral (cat scratch fever and lymphogranulo-
mavenereum), helminthic (schistosomiasis,
trichinosis, filariasis, and capillariasis), or
metallic (beryllium and zirconium). The
causes ofsomegranulomatous diseases (sar-
coidosis, Crohn's disease, and Wegener's
granulomatosis) are unknown (27).
Sarcoidosis is the granulomatous disease
that is clinically the most similar to CBD.
A careful occupational and environmental
history can be helpful, but even well-docu-
mented exposure to beryllium does not
eliminate the possibility of sarcoidosis.
Clinical findings that are (when present)
more characteristic of sarcoidosis include
extensive hilar adenopathy, spontaneous
remission, and the presence ofextrapul-
monary manifestations (e.g., erythema
nodosum, parotid involvement, bone
changes). Certain findings (variably present
in sarcoidosis) have never been reported in
a patient with CBD, including uveitis,
uveoparotid fever, cranial or peripheral
nerve involvement, and cystic bone lesions.
None of these clinical features is ade-
quatelysensitive orspecific toreliablydistin-
guish between sarcoidosis and CBD in indi-
vidual patients. Though not partoftheorig-
inal beryllium registry case definition, the
LPT is extremely useful in identifying indi-
viduals who have developed beryllium
hypersensitivity. Most notably, the LPT was
used to identify a cluster ofCBD in a metal
refinery after one worker questioned the
diagnosis of sarcoidosis given to him and
several co-workers (6). This test is nowavail-
able at a handful of medical centers in the
United States.
A number of medical tests (other than
theLPT) arealso useful in the quest toiden-
tify the cause of a patient's granulomatous
pulmonarydisease and assess thephysiologic
impact of the disease. The tests selected to
evaluate a new patient would typically
include 1) measurement ofangiotensin-con-
verting enzyme, a nonspecific marker ofdis-
ease activity; 2) chest radiograph to assess
the extent ofchest disease; 3) immune para-
meters and lymphocyte proliferative
responses to assess the immune system and
test forhypersensitivity to beryllium; 4) liver
function tests to assess liver involvement; 5)
review ofbiopsy slides for evidence ofinfec-
tion, malignancy, suppurative processes, and
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granulomatous processes; and 6) cultures
and microscopic examination of bron-
choalveolar lavage (BAL) fluid for evidence
ofinfection, malignancy, orhypersensitivity.
Summary
CBD has historically been a difficult diag-
nosis to make with certainty; the diagnosis
has typically required physicians to docu-
ment beryllium exposure by history or by
demonstrating excess beryllium in biologic
specimens, and to meet certain clinical and
pathologic criteria for chronic granuloma-
tous pulmonary disease, criteria that are
also present in other granulomatous dis-
eases such as sarcoidosis.
In routine medical practice, the lackofa
known (typically occupational) exposure
has usually precluded active consideration
of CBD in patients with granulomatous
disease. If no other etiology is found, sar-
coidosis has been the diagnosis ofexclusion.
This approach has rested upon unstated
assumptions that 1) the only significant
exposures are occupational; 2) the worker
and employer know about the exposure; 3)
the exposure is disclosed to the physician;
and 4) the physician understands the clini-
cal implications ofberyllium exposure.
Thevalidityofthese assumptions has not
been tested, and in some recent cases it is
demonstrably false. When the clinical find-
ings are consistent with granulomatous dis-
ease, CBD can now be diagnosed (or exclud-
ed) by assessing the immune response to
beryllium (28). This specialized testing
requires aprioricoordination with an appro-
priatelaboratory.
The best time to consider CBD is dur-
ing the initial evaluation of patients with
granulomatous pulmonary disease because
a diagnostic bronchoscopy is usually per-
formed. An LPT using BAL lymphocytes is
the gold standard for diagnosing or exclud-
ing CBD; while a positive LPT using
peripheral blood lymphocytes can also sup-
port the diagnosis, a negative test does not
exclude it.
Recommendations
The state of the art for beryllium-related
biomedical testing has advanced significant-
ly, and reliable testing is available in a few
centers. The following proposed guidelines
are intended to encourage physicians to con-
sider testing in the presence of uncertainty
about the potential forberyllium exposure:
1. A careful environmental and occupa-
tional history should be taken on every
new patient with granulomatous pul-
monary disease.
2. If beryllium exposure is documented, T
lymphocytes should be collected during
the initial bronchoscopy for the LPT; it
is also appropriate (but less sensitive) to
test lymphocytes from peripheral blood
for hypersensitivity to beryllium.
3. Ifberyllium exposure is not documented
(but cannot be excluded), collection ofT
lymphocytes for the LPT should be con-
sidered during the initial bronchoscopy;
it is also appropriate (but less sensitive)
to test lymphocytes from peripheral
blood for hypersensitivity to beryllium.
4. If beryllium exposure can be excluded
with reasonable confidence, the patient is
unlikely to benefit from beryllium-relat-
ed biomedical testing.
(Testing for beryllium hypersensi-
tivity requires apriori coordination with
an appropriate laboratory; a listing of
laboratories that perform the LPT is
maintained by the Beryllium Support
Group, P.O. Box 2021, Broomfield, CO
80038-2021 USA.)
To illustrate, a patient who once
worked at or lived by a foundry processing
metals from a variety of sources may have
beryllium exposure that has not been docu-
mented; thus, some uncertainty remains
and testing can reasonably be considered.
Uncertainties about beryllium exposure
can also be affected by a physician's knowl-
edge of industry; two physicians might
appropriately make different decisions
about testing in similar situations. The fol-
lowing points are offered to support the
consideration of testing when the patient's
potential for exposure is uncertain: 1)
chronic granulomatous disease is potential-
ly a life-threatening condition; 2) manage-
ment decisions and prognosis are clarified
by recognizing CBD; 3) the diagnostic test
(LPT) is very specific for beryllium hyper-
sensitivity when performed by an experi-
enced laboratory; 4) exposure and disease
can be widely separated in time and loca-
tion; 5) exposure histories are not always
reliable; and 6) a case of CBD can have
public health significance as a sentinel case.
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